NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
Cue received $481 million award to expand domestic production capacity of molecular, point-of-care COVID-19 tests
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
Rigel announced first patients enrolled in trial of fostamatinib in hospitalized COVID-19 patients in collaboration with Inova
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
OPKO Health’s BioReference Laboratories launched COVID-19 testing program for New York City schools
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
Pfizer Canada and BioNTech initiated rolling submission to Health Canada for SARS-CoV-2 vaccine candidate
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
NIH launched the Serological Sciences Network for COVID-19, announced grant and contract awardees
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
AMSP partnered with bioMerieux to facilitate supply of high-quality COVID-19 diagnostics
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
Gilead Sciences signed joint procurement agreement with European Commission for Vekluryﾮ (remdesivir)
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
Gilead Sciences updated supply and distribution of Vekluryﾮ (remdesivir) in the US
On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National…
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
Biotechnology | COVID-19 | Disease | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
Baricitinib had significant effect on recovery time, most Impactful in COVID-19 patients requiring oxygen
On Oct. 8, 2020, Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
Yale Cancer Center received NIH grant to fund COVID-19 research in patients with hematologic cancers
On Oct. 8, 2020, the National Institutes of Health (NIH) awarded a Research Project Cooperative Agreement grant to…
Johnson & Johnson announced EC approval of agreement to supply 200 million doses of COVID-19 vaccine candidate
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
Biotechnology | COVID-19 | Diagnostics | FDA
Abbott’s released ID NOW COVID-19 interim clinical study results to provide facts on clinical performance
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Mateon announced first patient enrolled in ARTI-19 multicenter interventional study of Artshield against COVID-19
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
Kindred Biosciences announced expansion of Manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…